Post-acute COVID-19 neuropsychiatric symptoms are not associated with ongoing nervous system injury.
Journal article
Taquet M. et al, (2024), Brain Commun, 6
GRIN2A (NR2A): a gene contributing to glutamatergic involvement in schizophrenia
Journal article
Harrison PJ. and Bannerman DM., (2023), Molecular Psychiatry
Acute blood biomarker profiles predict cognitive deficits 6 and 12 months after COVID-19 hospitalization.
Journal article
Taquet M. et al, (2023), Nat Med
Sex and age effects on risk of non-traumatic subarachnoid hemorrhage: Retrospective cohort study of 124,234 cases using electronic health records
Journal article
Harrison CH. et al, (2023), Journal of Stroke and Cerebrovascular Diseases, 32, 107196 - 107196
Data-driven Taxonomy for Antipsychotic Medication: A New Classification System
Journal article
McCutcheon R., (2023), Biological Psychiatry
Incidence of Epilepsy and Seizures Over the First 6 Months After a COVID-19 Diagnosis
Journal article
Taquet M. et al, (2023), Neurology, 100, e790 - e799
Neuropsychiatric disorders following SARS-CoV-2 infection
Journal article
HARRISON P. and Taquet M., (2023), Brain
Little evidence supports gabapentinoid use in bipolar disorder or insomnia.
Journal article
Saul H. et al, (2022), BMJ (Clinical research ed.), 379
Glutamatergic dysfunction leads to a hyper-dopaminergic phenotype through deficits in short-term habituation: a mechanism for aberrant salience.
Journal article
PANAGI M. et al, (2022), Molecular Psychiatry
CACNA1C (CaV1.2) and other L-type calcium channels in the pathophysiology and treatment of psychiatric disorders: Advances from functional genomics and pharmacoepidemiology.
Journal article
Harrison PJ. et al, (2022), Neuropharmacology
Cervical lymph nodes and ovarian teratomas as germinal centres in NMDA receptor-antibody encephalitis.
Journal article
Al-Diwani A. et al, (2022), Brain, 145, 2742 - 2754
Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients.
Journal article
Taquet M. et al, (2022), Lancet Psychiatry
New drug targets in psychiatry: Neurobiological considerations in the genomics era.
Journal article
Harrison PJ. et al, (2022), Neurosci Biobehav Rev, 139
Response to the letter by Lin et al.
Journal article
Taquet M. et al, (2022), Brain Behav Immun, 104
Impact of the COVID-19 Pandemic on the Global Delivery of Mental Health Services and Telemental Health: Systematic Review.
Journal article
Zangani C. et al, (2022), JMIR Ment Health
Using a generative model of affect to characterize affective variability and its response to treatment in bipolar disorder
Journal article
Pulcu E. et al, (2022), Proceedings of the National Academy of Sciences, 119
Six-month sequelae of post-vaccination SARS-CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections.
Journal article
Taquet M. et al, (2022), Brain Behav Immun, 103, 154 - 162
Brain-penetrant calcium channel blockers are associated with a reduced incidence of neuropsychiatric disorders.
Journal article
HARRISON P. and COLBOURNE C., (2022), Molecular Psychiatry
PAX-D: study protocol for a randomised placebo-controlled trial evaluating the efficacy and mechanism of pramipexole as add-on treatment for people with treatment resistant depression
Journal article
Au-Yeung SK. et al, (2022), Evidence Based Mental Health, 25, 77 - 83